Podcasts about jama network open

Mislabeled type 2 and gestational, told after giving birth she no longer had diabetes, an adult-onset type one spends years running dangerously high until an eye doctor finally catches it. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  ABLEnow save for today's needs or invest for tomorrow Eversense CGM Medtronic Diabetes Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 20% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Therapist Erika Forsyth on the emotional weight of diabetes: trusting your settings, hypervigilance and cortisol, the pre-bolus wait, identity and grief, and the self-compassion shown to lower stress and A1C. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  ABLEnow save for today's needs or invest for tomorrow Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 20% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-490 Overview: In the US, maternal morbidity and mortality rates are among the highest in the western world, and stroke is one of the leading causes—responsible for 1 of 12 maternal deaths. This rate is estimated to be much higher in high-risk pregnancies. Join us as we discuss a recent study examining rates of maternal stroke in which 1 in 4 women with stroke experienced a missed diagnostic opportunity and hear what these findings mean for your practice. Episode resource links: Haghighi N, Bourscheid RM, Shang C, et al. Identifying missed diagnostic opportunities in maternal stroke. Stroke. 2026;57(2). doi:10.1161/STROKEAHA.125.052995 Chen Y, Shiels MS, Uribe-Leitz T, et al. 2025. Pregnancy-Related Deaths in the US, 2018-2022. JAMA Network Open.  Lappen JR, Pettker CM, Louis JM. 2021. American Journal of Obstetrics and Gynecology. Society for Maternal-Fetal Medicine Consult Series #54: Assessing the Risk of Maternal morbidity and Mortality. American Journal of Obstetrics and Gynecology. Miller EC, Bello NA, Chen PR, et al 2026. Prevention and Treatment of Maternal Stroke in Pregnancy and Postpartum: A Scientific Statement from the American Heart Association. Stroke.  Bushnell C, Kernan WN, Sharrief AZ, et al. 2024. Guideline for the Primary Prevention of Stroke: A Guideline from the American Heart Association/¬American Stroke Association. Stroke.  Guest: Susan Feeney, DNP, FNP-BC, NP-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-490 Overview: In the US, maternal morbidity and mortality rates are among the highest in the western world, and stroke is one of the leading causes—responsible for 1 of 12 maternal deaths. This rate is estimated to be much higher in high-risk pregnancies. Join us as we discuss a recent study examining rates of maternal stroke in which 1 in 4 women with stroke experienced a missed diagnostic opportunity and hear what these findings mean for your practice. Episode resource links: Haghighi N, Bourscheid RM, Shang C, et al. Identifying missed diagnostic opportunities in maternal stroke. Stroke. 2026;57(2). doi:10.1161/STROKEAHA.125.052995 Chen Y, Shiels MS, Uribe-Leitz T, et al. 2025. Pregnancy-Related Deaths in the US, 2018-2022. JAMA Network Open.  Lappen JR, Pettker CM, Louis JM. 2021. American Journal of Obstetrics and Gynecology. Society for Maternal-Fetal Medicine Consult Series #54: Assessing the Risk of Maternal morbidity and Mortality. American Journal of Obstetrics and Gynecology. Miller EC, Bello NA, Chen PR, et al 2026. Prevention and Treatment of Maternal Stroke in Pregnancy and Postpartum: A Scientific Statement from the American Heart Association. Stroke.  Bushnell C, Kernan WN, Sharrief AZ, et al. 2024. Guideline for the Primary Prevention of Stroke: A Guideline from the American Heart Association/¬American Stroke Association. Stroke.  Guest: Susan Feeney, DNP, FNP-BC, NP-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Send us Fan MailPhototherapy duration, jaundice and UTIs, extended CPAP, and The Pitt. A full week on the Incubator Journal Club.Ben opens with a nationwide Swedish cohort study from JAMA Network Open examining phototherapy duration in nearly 5,000 very preterm infants. Longer phototherapy was not significantly associated with late neonatal mortality, but six to seven days was associated with significantly higher rates of severe neonatal morbidity. With 95% of the cohort receiving phototherapy, Ben and Daphna question how much evidence actually supports the near-universal practice.Daphna follows with a retrospective study from Istanbul showing that 31% of term and near-term neonates hospitalized for unexplained hyperbilirubinemia had culture-proven UTIs, with pathological renal ultrasound findings independently associated with a 4.6-fold increased odds of UTI.Ben then reviews the extended CPAP secondary analysis by Mamidi and McEvoy, showing that two additional weeks of bubble CPAP reduced intermittent hypoxemia episodes from 151.7 to 57.6 compared to discontinued CPAP.Daphna closes with the NEOASP five-day UTI treatment guideline from Nationwide Children's Hospital, where a structured stewardship approach yielded a 1% failure rate.Ben and Eli close the week reflecting on The Pitt and what it reveals about the broken realities of American healthcare.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Today's podcast is a natural follow up to our podcasts on Slow Codes and Unilateral DNR orders.Today we talk about a new study about how clinicians talk about potentially non-beneficial life-prolonging treatments, published in JAMA Network Open. Do they adhere to society guidelines, which allow as permissible approaches only shared decision-making and following institutional policy.  Or do they take alternative approaches, like not offering interventions, not mentioning interventions, or simply stating a plan to limit interventions? Turns out doctors are using these alternative approaches frequently. Our guests are Jason Batten, Liz Dzeng, and Teva Brender, all clinicians, all of whom have been thinking about and wrestling with the ethical reasoning behind these approaches. We all admit to using these approaches.  Are the alternative approaches wicked games (song hint), and our response should be to stop these behaviors, beginning with ourselves? After all, if you ask patients or surrogates, they're likely to say they want all the options and may not universally welcome recommendations.  Or, as with slow codes, does the fact that these alternative approaches are in common use suggest that the guidelines should be revised?  You listen and decide! -Alex Smith   Additional links: Dzeng 2023 JAMA IM: The larger ethnographic study from which data was drawn with data drawn from high- medium- and low-intensity hospitals. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2806959 Brender 2025 JAMA NO: Factors that exacerbate or mitigate moral distress related to potentially non-beneficial treatments.https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835316 Dzeng 2015 JAMA IM: Study illustrating that more senior physicians feel more comfortable not offering or recommending against futile CPR. Relevant quote: "Experienced physicians at all sites generally were comfortable engaging in best interest decision making and, when clinically appropriate, not offering or making explicit recommendations against offering resuscitation." https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2212265 Weiss Goitiandia AJOB 2025: Reasons why some clinicians would hesitate to go to the ethics committee / futility process for these discussions: https://www.tandfonline.com/doi/10.1080/15265161.2025.2457734?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Axelrod AJOB 2025: Discusses some of the systemic consequences of using physiologic futility as a standard and how it might contribute to a healthcare system that imposes aggressive treatments on vulnerable patients. https://www.tandfonline.com/doi/full/10.1080/15265161.2025.2530715#d1e152  

This episode of the PeerDirect Medical News Podcast reviews three developments with potential implications across nephrology, oncology, and public health. Highlights include the FIND-CKD trial showing finerenone may slow disease progression in chronic kidney disease patients without diabetes, seven-year CROWN trial data demonstrating durable long-term disease control with lorlatinib in advanced ALK-positive lung cancer, and a JAMA Network Open study linking measles-related vitamin A misinformation to increased toxic exposures. Together, these findings underscore evolving treatment paradigms and the growing impact of health communication on patient outcomes.

A headline like “weight loss drugs may reduce breast cancer risk” grabs attention fast, but the real story lives in the fine print. We take you through a new Penn Medicine study that observed lower breast cancer rates among women with overweight or obesity who used GLP-1 medications, then we translate what that finding actually means in plain language. Observational data can reveal a signal worth studying, but it cannot prove the medication caused the outcome, and that distinction matters for your decisions and your expectations. We also zoom out to the bigger why: obesity is not just about body size. Fat tissue is biologically active, shaping chronic inflammation, estrogen exposure after menopause, insulin resistance, and even how well the immune system spots abnormal cells. Those pathways help explain why obesity is linked to many cancers, including postmenopausal breast cancer, and why researchers are curious whether effective obesity treatment could shift risk over time. Then we get practical. We review what stronger evidence from randomized controlled trials says so far: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound do not appear to increase breast cancer risk in the available trial data, even though most trials were not designed to study cancer outcomes for many years. We also discuss why newer studies seem most suggestive for hormone receptor positive breast cancer, along with the leading theories: weight loss itself, improved metabolic health and insulin signaling, reduced inflammation, and the still-unclear possibility of direct GLP-1 effects in cancer biology. If you like evidence-based medicine with real-world context (and a little Philly-life banter), subscribe, share this episode with a friend, and leave a review so more people can find the show. What question do you want answered next about GLP-1s, obesity treatment, or cancer risk?ReferencesRisk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-Analysis. Ko A, Chang YC, Bahar F, et al. Annals of Internal Medicine. 2025;. doi:10.7326/ANNALS-25-02237.Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis. Piccoli GF, Mesquita LA, Stein C, et al. The Journal of Clinical Endocrinology and Metabolism. 2021;106(3):912-921. doi:10.1210/clinem/dgaa891.Glucagon-Like Peptide 1 Receptor Agonists and Cancer Risk: The Good, the Bad and the Unknown. Mannucci E, Dicembrini I. Nature Reviews. Clinical Oncology. 2026;23(6):459-470. doi:10.1038/s41571-026-01135-0.GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women. McDonald ES, Gillis LB, Gabriel P, et al. JCO Oncology Practice. 2026;:101200OP2600485. doi:10.1200/OP-26-00485.GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.. Shah Z, Hundal J, Afridi S, et al. Journal of Clinical Oncology. 2026;44(Suppl 16):10548. doi:10.1200/JCO.2026.44.16_suppl.10548.Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer. Tatum KL, Dahman B, Stevenson A, et al. JAMA Network Open. 2026;9(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133.Association of Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cancers-Evidence From a Drug Target Mendelian Randomization and Clinical Trials. Sun Y, Liu Y, Dian Y, et al. International Journal of Surgery (London, England). 2024;110(8):4688-4694. doi:10.1097/JS9.0000000000001514.GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.. Guo Cheng and Amanda Ward. Journal of Clinical Oncology. 2025;43(Suppl 16):10557. doi:10.1200/JCO.2025.43.16_suppl.10557.Glucagon-Like Peptide-1 Analogues and Risk of Breast Cancer in Women With Type 2 Diabetes: Population Based Cohort Study Using the UK Clinical Practice Research Datalink. Hicks BM, Yin H, Yu OH, et al. BMJ (Clinical Research Ed.). 2016;355:i5340. doi:10.1136/bmj.i5340.GLP-1 Receptor Agonists and Cancer: Current Clinical Evidence and Translational Opportunities for Preclinical Research. Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. The Journal of Clinical Investigation. 2025;135(21):e194743. doi:10.1172/JCI194743.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Nutritionist Leyla Muedin discusses research showing simple strength tests—grip strength and a five-rep sit-to-stand chair test—predict longevity in older women. In a University at Buffalo study of over 5,000 women ages 63–99 followed for eight years, stronger grip and faster chair-stand times were linked to lower mortality; every additional 7 kg of grip strength corresponded to a 12% reduction in death risk, and faster chair-stands were also associated with improved survival, even after adjusting for activity, cardiovascular fitness, and inflammation. She emphasizes prioritizing muscle-strengthening alongside aerobic exercise and suggests accessible resistance options (weights, bodyweight moves, or household items) with professional guidance as needed. She then cites UK Biobank data linking long-term statin use to declines in grip strength and appendicular lean mass, urging discussion with physicians and added vigilance, especially for those also using GLP-1 drugs that may reduce protein intake and muscle mass.

What's up all you stoners! Mr. and Mrs. Weedman are back with another round of cannabis headline news, medical marijuana research, industry updates, and a few stoner stories along the way—all in an effort to #StompTheStigma and #FreeThePlant.Before diving into the news, they get normal while seshing on some Black Maple from Soil Syndicate. This week, Mr. Weedman discusses whether cannabis consumers still hide their use, a major new study published in JAMA Network Open, and the growing battle over federal marijuana rescheduling, hemp regulations, and cannabis business reforms.Mrs. Weedman breaks down a medical cannabis guide for new patients, reviews research showing significant pain relief for fibromyalgia, rheumatoid arthritis, and osteoarthritis patients, and explores a thought-provoking discussion about cannabis and Christianity.The duo also covers cannabis policy updates from across the U.S., veterans' access, hemp THC legislation, international cannabis developments, and the latest stories shaping the future of legalization.As always, expect cannabis advocacy, laughs, stoner stories, and organic conversation from Mr. & Mrs. Weedman as they break down the week's hottest weed headlines.Articles Covered: https://thefreshtoast.com/culture/do-cannabis-consumers-still-hide-their-use/https://internationalhighlife.com/medical-cannabis-guide/https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848548https://www.marijuanamoment.net/cannabis-provides-significant-improvements-in-pain-for-fibromyalgia-rheumatoid-arthritis-and-osteoarthritis-patients-study-shows/?utm_source=flipboard&utm_content=Cpizzo721%2Fmagazine%2FMarijuana+Investinghttps://illinoisnewsjoint.com/illinois-legislators-pass-cannabis-omnibus-bill/#CannabisPodcast #MarijuanaNews #CannabisNews #MedicalMarijuana #CannabisLegalization #HempNews #420Podcast #WeedCulture #CannabisCommunity #Weedman420ChroniclesThanks for listening and supporting independent cannabis media. Support The Show: https://www.buzzsprout.com/283607/supportTWITTER: @weedman420podYouTube: Weedman420 ChroniclesEMAIL:  weedman420chronicles@gmail.comSHOP: www.eightdecades.comIG: @eightdecadesEMAIL: eightdecadesinfo@gmail.comMr & Mrs "get normal" seshing on: Black Maple from @TheSoilSyndicateCOPYRIGHT 2021 WeedMan420Chronicles©Suggestions? Questions? Chat with us here.Support the show

Back in June 2024, we highlighted surprising data from JAMA Network Open regarding adolescent care in the ED. Because many adolescents use the ED as their primary care provider, it's a good opportunity for them to have contraception addressed regardless of why they presented. But that's not what was happening. That publication from two years ago showed significant gaps in addressing contraception in the ED to pregnancy vulnerable young women, mainly teens. We covered those results back then and said that that would be a wonderful QI project for any resident or medical students to work with their hospital ED to improve that. Well, now a similar publication, looking at a different target- STI empiric treatment among pregnant women in the ED, has been published with that same vibe. Yep, there are BIG discrepancies in what pregnant women are given- or in this case, NOT GIVEN, in the ED compared to their nonpregnant peers. This was published in mid-April 2026. Two big questions remain unanswered in this data. Listen in for details. 1. Gottlieb M, Moyer E, Slocum GW, et al. Sexually Transmitted Infection Treatment Rates Among Pregnant vs Nonpregnant Patients in Emergency Departments. JAMA Network Open. 2026. 2. Canter H, Reed J, Palmer C, et al. Contraception Use and Pregnancy Risk Among Adolescents in Pediatric Emergency Departments. JAMA Netw Open. 2024;7(6):e2418213. doi:10.1001/jamanetworkopen.2024.18213

As kids, we all remember the phrase “eat your veggies.” Now, new research from Sweden suggests there might be a little wiggle room. The study, published in JAMA Network Open,...

There's a single number on your routine blood test that predicts your risk of dying from cancer, heart disease, and infection better than cholesterol — and an FDA-approved drug may now move it.In this Health Longevity Secrets explainer, Robert Lufkin MD breaks down lymphopenia, the IL-15 cytokine, and ANKTIVA (nogapendekin alfa inbakicept) — the first FDA-approved IL-15 super-agonist and possibly one of the most important longevity drugs of the decade.CHAPTERS: 00:00 — Introduction: The Blood Test Number Better Than Cholesterol 00:35 — What Is Lymphopenia and Why It Matters 01:50 — Immunosenescence: Why Your T Cells Decline After Age 20 02:30 — The Mortality Data: Three Studies on Lymphopenia 03:20 — Copenhagen Study: 63% Higher All-Cause Mortality 03:50 — Coronary Angiography Study: Hazard Ratio 1.97 04:25 — Enter IL-15: The Cytokine That Builds Killer Immune Cells 05:15 — IL-15 as a Myokine: Why Resistance Training Protects Against Cancer 06:00 — Four Hallmarks of Aging Hit By One Molecule 06:30 — ANKTIVA Explained: The IL-15 Super-Agonist 07:00 — FDA Approval, Bladder Cancer, and the Soon-Shiong Reframe 08:15 — Is ANKTIVA a Longevity Drug? The Bullish Case 09:00 — The Skeptical Case: Why We Don't Know Yet 10:15 — What You Can Do Today: Track Your Number, Raise IL-15 Naturally 11:30 — Final Take and ClosingKEY TAKEAWAYS:Lymphopenia (absolute lymphocyte count below 1,500/μL) predicts all-cause mortality better than cholesterol in multiple large cohort studiesIL-15 expands NK cells and CD8+ T cells — the same cells that clear senescent "zombie" cells and patrol for cancerResistance training is the single strongest known endogenous IL-15 stimulus; your muscle signals your immune system to stay youngANKTIVA is the first FDA-approved IL-15 super-agonist (April 2024) — currently for bladder cancer but being reframed as a lymphopenia treatmentIL-15 hits four hallmarks of aging at once: immunosenescence, senescent cell accumulation, chronic inflammation, and sarcopeniaHonest take: exciting hypothesis with FDA approval, but zero human longevity trials yet — watch this spaceSTUDIES & SOURCES MENTIONED:Zidar et al., JAMA Network Open 2019 — Lymphopenia and mortality in 31,178 US adults (NHANES)Warny et al., CMAJ 2020 — Copenhagen General Population Study, lymphopenia in 108,135 adultsBawamia et al., Cardiology Journal 2022 — Lymphopenia and 8-year mortality in 15,179 coronary angiography patientsFDA approval, April 22, 2024 — Nogapendekin alfa inbakicept-pmln (ANKTIVA) for BCG-unresponsive non-muscle invasive bladder cancerWatch the full video on YouTube: https://youtu.be/220KHIdFCwg

Groundbreaking Study Reveals Psilocybin Can CRUSH Smoking Addiction | Dr Matt Johnson Psilocybin Beats Nicotine Patches in BREAKTHROUGH Smoking Trial | Dr Matt Johnson Johns Hopkins Scientist Reveals Psilocybin OUTPERFORMS Patches for Smokers | Dr Matt Johnson Matt Johnson joins Rav Arora on The Illusion of Consensus to discuss his new JAMA Network Open study on psilocybin, nicotine patches, CBT and smoking cessation. A Johns Hopkins psychiatry and behavioural sciences professor, Johnson has been central to modern psychedelic research, including work on psilocybin for addiction, depression and end of life distress. He explains why one psilocybin session paired with CBT showed higher six month smoking abstinence rates than nicotine patch treatment with CBT, and what that could mean for tobacco use disorder. The discussion also covers vaping, nicotine harm reduction, the UK Tobacco and Vapes Bill, addiction treatment, mystical experiences, emotional breakthrough, neuroplasticity, agency and why psychedelics may help people change entrenched behaviour. Rav and his guest examine both the promise and the risks of psychedelic therapy, including bad experiences, vulnerable patients, clinical safeguards and the future of FDA approved addiction treatments. Link to Matt's Paper: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2846155 Subscribe to Rav's Substack for exclusive content: https://www.illusionconsensus.com/

What if the anxiety, overthinking, people pleasing, emotional shutdown, hypervigilance, burnout, and relationship struggles you experience today… were never actually "you" to begin with? In this deeply personal and profoundly eye-opening solo episode, Darin Olien dives into the hidden nervous system programming formed between the ages of 0 and 8 that silently shapes our adult lives. Drawing from neuroscience, trauma research, attachment theory, epigenetics, somatic healing, and his own emotional breakthroughs, Darin explores how childhood experiences become subconscious operating systems that influence everything from relationships and stress responses to chronic disease and self-worth. This episode is a powerful roadmap toward healing. Darin breaks down the science behind trauma, the ACE study, nervous system dysregulation, emotional patterning, and neuroplasticity, while also sharing practical tools like somatic experiencing, expressive writing, EMDR, and Internal Family Systems to help listeners begin rewiring their emotional lives from the inside out. What You'll Learn How childhood experiences program the nervous system Why most adult emotional reactions are subconscious survival patterns The connection between trauma, stress hormones, and chronic disease How the nervous system stores emotional experiences in the body Why people pleasing, hypervigilance, burnout, and emotional shutdown develop The science behind neuroplasticity and rewiring the brain What the ACE Study revealed about childhood trauma and adult health How trauma impacts the amygdala, hippocampus, and stress-response systems Why emotional patterns are adaptations, not character flaws How epigenetics can pass trauma responses across generations The role of somatic experiencing in trauma healing Practical tools for emotional regulation and nervous system repair Chapters 00:00:03 – Welcome to SuperLife 00:00:32 – Sponsor: Bite Toothpaste and eliminating toxic plastic exposure 00:02:47 – Darin introduces emotional reactions and nervous system triggers 00:03:15 – A personal story about reacting vs responding in conflict 00:03:50 – Emotional shutdowns, rage, withdrawal, people pleasing, and overcorrection 00:04:19 – Darin's physical pain journey and emotional discoveries in 2025 00:04:42 – Birth trauma, childhood conditioning, and nervous system programming 00:05:04 – Why the ages of 0–8 are the most neurologically influential years 00:05:18 – Theta and delta brainwave states during childhood 00:05:55 – How children absorb emotional patterns without filters 00:06:22 – Childhood experiences becoming subconscious operating systems 00:06:44 – Adults unknowingly living through a 5-year-old nervous system 00:07:12 – Why this episode became deeply personal for Darin 00:07:35 – The neuroscience behind stress responses and emotional conditioning 00:08:17 – Brain development, neuroplasticity, and subconscious programming 00:09:13 – How the HPA axis, amygdala, and prefrontal cortex are shaped early in life 00:09:45 – Core childhood questions that program the nervous system 00:10:29 – Why adult stress responses originate in childhood environments 00:11:05 – Research showing childhood adversity alters brain structure and chemistry 00:11:18 – The ACE Study explained 00:11:49 – Why patients losing weight became emotionally overwhelmed 00:12:18 – The ten categories of adverse childhood experiences 00:13:02 – "The health crisis of America begins in childhood" 00:13:36 – How adverse childhood experiences increase disease risk 00:14:03 – Suicide, alcoholism, autoimmune disease, depression, and trauma correlations 00:14:37 – Chronic disease as a nervous system issue 00:15:04 – Survival mode, inflammation, hormonal dysregulation, and emotional scarcity 00:15:42 – Self-sabotage and emotional coping patterns explained 00:16:02 – Why your emotional patterns are not character flaws 00:16:22 – Childhood survival adaptations and nervous system intelligence 00:16:52 – Hypervigilance, people pleasing, rage, emotional shutdown, and fear 00:17:05 – Sponsor: Manna Vitality and frequency-based wellness 00:18:59 – Epigenetics and inherited trauma responses 00:19:22 – Cortisol regulation genes and hyperactive stress responses 00:19:51 – Holocaust survivors, inherited trauma, and generational nervous systems 00:20:19 – Why healing requires nervous system awareness—not just intellectual understanding 00:20:45 – "You were never supposed to get over it—you were supposed to heal from it" 00:21:01 – Real-life examples of subconscious nervous system programming 00:21:16 – Why receiving compliments can feel unsafe 00:21:30 – Darin's personal struggle with overachievement and scarcity programming 00:22:03 – Emotional neglect, chronic striving, and feeling "not enough" 00:22:16 – The nervous system roots of burnout and exhaustion 00:22:23 – Hair-trigger emotional reactions and hyperactive amygdala responses 00:22:38 – Chronic self-abandonment and losing personal boundaries 00:22:52 – Fear of intimacy, trust issues, and emotional safety 00:23:02 – "The body keeps the score" explained 00:23:22 – Trauma stored in posture, breath, digestion, immunity, and emotional regulation 00:23:43 – Harvard research on trauma-related brain changes 00:24:19 – The radical power of neuroplasticity and nervous system rewiring 00:24:48 – Why healing requires conscious participation 00:25:01 – Darin shares how healing changed decades of emotional pain 00:25:33 – Somatic Experiencing and Peter Levine's trauma work 00:25:57 – How animals discharge stress naturally 00:26:23 – Trauma as incomplete physiological responses frozen in the body 00:26:42 – Why humans suppress emotional discharge 00:27:16 – PTSD research and the effectiveness of somatic experiencing 00:27:41 – A step-by-step somatic grounding practice 00:28:14 – Why healing is more powerful with a regulated person beside you 00:28:38 – EMDR and reprocessing traumatic experiences 00:28:55 – Internal Family Systems and the "parts" inside the psyche 00:29:13 – Inner critics, overachievers, and nervous system adaptations 00:29:39 – Compassionately listening to emotional parts instead of suppressing them 00:29:51 – Expressive writing as a trauma healing practice 00:30:22 – The neuroscience behind emotional journaling 00:30:48 – A four-day expressive writing protocol for healing 00:31:05 – "You are not broken" 00:31:16 – Reprogramming the nervous system through love and safety 00:31:37 – Why deep healing happens in the presence of another regulated person 00:31:52 – Darin considers creating a future healing workshop 00:32:04 – Final reflections: "You are not what happened to you" 00:32:12 – Peace. Love. SuperLife. Thank You to Our Sponsors Bite Toothpaste: Go to trybite.com/DARIN20 or use code DARIN20 for 20% off your first order Manna Vitality: Go to mannavitality.com/ and use code DARIN12 for 12% off your order. Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only $7.49/month at https://patreon.com/darinolien     Connect with Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness Key Takeaway "The emotional patterns, fears, reactions, and coping mechanisms that run your adult life are often survival adaptations created by your nervous system during childhood. They are not your identity. They are not permanent. And through awareness, somatic healing, emotional processing, nervous system regulation, and conscious repetition, those deeply rooted patterns can be rewritten into something healthier, freer, and more aligned with who you truly are." Bibliography/Sources Neuroscience & Early Programming Agorastos, A., Pervanidou, P., Chrousos, G. P., & Baker, D. G. (2019). Developmental trajectories of early life stress and trauma: A narrative review on neurobiological aspects beyond stress system dysregulation. Frontiers in Psychiatry, 10, Article 118. https://doi.org/10.3389/fpsyt.2019.00118 Bolton, J. L., Short, A. K., Simeone, K. A., Daglian, J., & Baram, T. Z. (2019). Programming of stress-sensitive neurons and circuits by early-life experiences. Frontiers in Behavioral Neuroscience, 13, Article 30. https://doi.org/10.3389/fnbeh.2019.00030 Shonkoff, J. P., & Boyce, W. T. (2024). Toxic stress and developmental programming of the HPA axis. Annual Review of Developmental Psychology. https://www.annualreviews.org/journal/devpsych Teicher, M. H., & Ohashi, K. (2023). Childhood trauma and reduced hippocampal, anterior cingulate, and corpus callosum volumes. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry van der Kolk, B. A. (2014). The body keeps the score: Brain, mind, and body in the healing of trauma. Viking / Penguin. https://www.penguinrandomhouse.com/books/313183/the-body-keeps-the-score-by-bessel-van-der-kolk-md/ ACE Study & Adverse Childhood Experiences Felitti, V. J. (2002). The relation between adverse childhood experiences and adult health: Turning gold into lead. The Permanente Journal, 6(1), 44–47. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112216/ Felitti, V. J., & Anda, R. F. (2010). The relationship of adverse childhood experiences to adult health, well-being, social function, and healthcare. In R. Lanius, E. Vermetten, & C. Pain (Eds.), The impact of early life trauma on health and disease (pp. 77–87). Cambridge University Press. https://doi.org/10.1017/CBO9780511777042 Hillis, S., Mercy, J., Amobi, A., & Kress, H. (2023). Economic burden of health conditions associated with adverse childhood experiences among U.S. adults. JAMA Network Open, 6(12). https://jamanetwork.com/journals/jamanetworkopen Liu, Y., Croft, J. B., Chapman, D. P., et al. (2013). Associations between adverse childhood experiences and health outcomes in adults aged 18–59 years. PLOS ONE, 8(3), e58625. https://doi.org/10.1371/journal.pone.0058625 Epigenetics & Trauma Baratta, M. V., et al. (2021). Epigenetics of childhood trauma: Long term sequelae and potential for treatment. Neuroscience & Biobehavioral Reviews, 132, 1049–1063. https://doi.org/10.1016/j.neubiorev.2021.09.043 Jiang, S., Postovit, L., Cattaneo, A., Binder, E. B., & Aitchison, K. J. (2019). Epigenetic modifications in stress response genes associated with childhood trauma. Frontiers in Psychiatry, 10, Article 808. https://doi.org/10.3389/fpsyt.2019.00808 Provençal, N., & Binder, E. B. (2015). The effects of early life stress on the epigenome: From the womb to adulthood and even before. Experimental Neurology, 268, 10–20. https://doi.org/10.1016/j.expneurol.2014.12.001 Healing Modalities — Research Brom, D., Stokar, Y., Lawi, C., et al. (2017). Somatic experiencing for posttraumatic stress disorder: A randomized controlled outcome study. Journal of Traumatic Stress, 30(3), 304–312. https://doi.org/10.1002/jts.22189 Fratarolli, J. (2006). Experimental disclosure and its moderators: A meta-analysis. Psychological Bulletin, 132(6), 823–865. https://doi.org/10.1037/0033-2909.132.6.823 Gilbert, P. (2009). The compassionate mind: A new approach to life's challenges. New Harbinger Publications. https://www.newharbinger.com/9781572248403/the-compassionate-mind/ Justice Resource Institute. (2022). Evaluation of the efficacy of Internal Family Systems (IFS) therapy for trauma-related symptoms among complexly traumatized adults. ClinicalTrials.gov Identifier: NCT05155930. https://clinicaltrials.gov/ct2/show/NCT05155930 Kuhfuß, M., Maldei, T., Hetmanek, A., & Baumann, N. (2021). Somatic experiencing — effectiveness and key factors of a body-oriented trauma therapy. European Journal of Psychotraumatology, 12(1), Article 1929023. https://doi.org/10.1080/20008198.2021.1929023 Levine, P. A. (2010). In an unspoken voice: How the body releases trauma and restores goodness. North Atlantic Books. https://www.northatlanticbooks.com/shop/in-an-unspoken-voice/ Neff, K. D., & Germer, C. K. (2013). A pilot study and randomized controlled trial of the Mindful Self-Compassion Program. Journal of Clinical Psychology, 69(1), 28–44. https://doi.org/10.1002/jclp.21923 Pennebaker, J. W. (1997). Writing about emotional experiences as a therapeutic process. Psychological Science, 8(3), 162–166. https://doi.org/10.1111/j.1467-9280.1997.tb00403.x Rodenburg, R., Benjamin, A., de Roos, C., Meijer, A. M., & Stams, G. J. (2009). Efficacy of EMDR in children: A meta-analysis. Clinical Psychology Review, 29(7), 599–606. https://doi.org/10.1016/j.cpr.2009.06.008 Schwartz, R. C. (2021). No bad parts: Healing trauma and restoring wholeness with the Internal Family Systems model. Sounds True. https://www.soundstrue.com/products/no-bad-parts Shapiro, F. (2017). Eye movement desensitization and reprocessing (EMDR) therapy: Basic principles, protocols, and procedures (3rd ed.). Guilford Press. https://www.guilford.com/books/Eye-Movement-Desensitization-and-Reprocessing/Francine-Shapiro/9781462532766  

Five longevity beliefs that millions have followed for decades have just been overturned by the latest research. Some of these will surprise you.In this explainer, Robert Lufkin MD walks through five of the most widely believed longevity myths — and what the most recent science actually says about each one. From genetics and middle age to antioxidants, alcohol, and caloric restriction, the evidence has shifted dramatically.CHAPTERS:00:00 — Introduction00:32 — Myth 1: Your Genes Determine How Long You Live01:51 — Myth 2: It's Too Late to Change After Middle Age03:24 — Myth 3: Antioxidant Supplements Prevent Disease05:22 — Myth 4: Moderate Alcohol Is Good for You07:04 — Myth 5: Caloric Restriction Is King08:50 — The Real Framework: Quality Beats Quantity09:18 — Final TakeawayKEY TAKEAWAYS:• Genetics accounts for at most 25–50% of how long you live• Quitting smoking before 40 eliminates ~90% of excess mortality risk• Antioxidant supplements have no benefit and may increase mortality• The protective J-curve for moderate alcohol disappears once you correct for the "sick quitter" effect• Caloric restriction's primate magic was rescuing animals from a high-sugar control diet• Diet quality matters more than diet quantitySTUDIES & SOURCES MENTIONED:• Herskind et al., Human Genetics 1996 — 2,872 Danish twin pairs heritability of longevity• Jha et al., NEJM 2013 — 21st-century smoking cessation and life expectancy• Saint-Maurice et al., JAMA Network Open 2019 — Adult life-course physical activity and mortality• Bjelakovic et al., Cochrane 2012 — Antioxidant supplements for prevention of mortality• Zhao et al., JAMA Network Open 2023 — Daily alcohol intake and all-cause mortality meta-analysis• Mattison et al., Nature Communications 2017 — Caloric restriction in rhesus monkeys (NIA / Wisconsin reconciliation)⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!New episodes every Tuesday & Thursday. Subscribe so you don't miss one.Continue this conversation on Substack: https://robertlufkinmd.substack.comLies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/Web: https://www.robertlufkinmd.comYouTube: https://www.youtube.com/robertlufkinmdX: https://x.com/robertlufkinmdInstagram: https://www.instagram.com/robertlufkinmd/TikTok: https://www.tiktok.com/@robertlufkinLinkedIn: https://www.linkedin.com/in/robertlufkinmd/

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

Send us Fan MailBen kicks things off with a major career update before we dive into a critical study from JAMA Network Open. We explore the predictive value of the five minute Apgar score when combined with umbilical artery pH in very preterm infants. While the Apgar score was originally designed for term babies, this analysis of the EPICE cohort reveals its enduring utility even in the smallest patients. We discuss how these two measures interact, which one "wins" when they conflict, and why the clinician assessment remains a powerful predictor of mortality and severe morbidity in the NICU.----Apgar Score Plus Umbilical Artery pH and Adverse Neonatal Outcomes in Very Preterm Infants. Ehrhardt H, Behboodi S, Maier RF, Aubert AM, Ådén U, Staude B, Draper ES, Gudmundsdottir A, Siljehav V, Varendi H, Weber T, Zemlin M, Zeitlin J; EPICE/SHIPS Research Group.JAMA Netw Open. 2026 Feb 2;9(2):e2557913.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

In this episode of SoundPractice, host Mike Sacopulos speaks with two physician-researchers whose landmark study is sounding an early warning about the long-term consequences of state abortion restrictions on the U.S. physician workforce. Anisha Ganguly, MD, MPH, assistant professor of medicine at the University of North Carolina at Chapel Hill, and Anna Morenz, MD, MPH, assistant clinical professor of internal medicine at the University of Arizona, discuss their study published in JAMA Network Open in March 2026. Their study analyzed nearly 24.2 million residency applications submitted to more than 4,300 programs across all medical specialties between the 2018–2019 and 2022–2023 application cycles. Using an interrupted time-series causal methodology developed in collaboration with health economist Anirban Basu, PhD, MS, at the University of Washington, the team found that applications to programs in states enacting new abortion restrictions after Dobbs dropped significantly — among both male and female applicants. Among the conversation's most striking moments: Ganguly reveals that the decline among men applicants was larger than expected — and larger than they had originally hypothesized. She and Morenz discuss why this makes Dobbs an “all of us” problem, not just a women's issue, and what it signals about the broader reproductive climate of restricted states. The episode also covers the pipeline problem: because more than half of physicians ultimately practice in the state where they trained, sustained declines in application volume could worsen existing physician shortages in primary care and emergency medicine in restricted states for years to come. Morenz shares a timely update: in the most recent March 2026 match cycle, two OB-GYN residency programs — both in Texas — failed to fill all their slots. Study Reference: Ganguly AP, Basu A, Morenz AM. State-Level Disparities in Residency Applications After Dobbs v Jackson Women's Health Organization. JAMA Netw Open. 2026;9(3):e260286. doi:10.1001/jamanetworkopen.2026.0286 Learn more about the American Association for Physician Leadership at www.physicianleaders.org.

Send us Fan MailIn this episode of Journal Club, Ben and Daphna dive into the results of the NIRTURE trial, recently published in JAMA Network Open. Building on the lessons of SafeBoosC 3 , the NIRTURE investigators aimed to reduce the burden of cerebral hypoxia and hyperoxia in extremely preterm infants using a standardized NIRS guided treatment protocol. While the study showed a dramatic improvement in maintaining cerebral normoxia, driven largely by a reduction in hyperoxia , the clinical outcomes before discharge remained neutral. Join us as we discuss whether regional oximetry is a must have bedside tool or just another data point in search of a clear clinical benefit.  ----Cerebral Oximetry-Guided Treatment and Cerebral Oxygenation in Extremely Preterm Infants: A Randomized Clinical Trial. Jani PR, Goyen TA, Balegar KK, Maheshwari R, Saito-Benz M, Schindler T, Moore J, Merhi M, Cruz M, Song Y, McDonagh H, Luig M, Tracy M, D'Cruz D, Perdomo A, Morakeas S, Dasireddy V, Culcer M, Shingde V, Bennington K, Michalowski J, Fucek A, Querim J, Stevens S, Santanelli J, Elhindi J, Gloss B, Halliday R, Shah D, Popat H.JAMA Netw Open. 2026 Feb 2;9(2):e2557620. Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

The latest Household Food Security report estimated that 13.7% of U.S. households experienced food insecurity in 2024. This lack of access to a nutritious diet can significantly affect health, so how does it then impact older adults' health and their risk for cognitive impairment? Dr. Heejin Lee joins the podcast to share what food insecurity means, how it can affect a person's overall health and what her study found about its effect on dementia and cognitive impairment, as well as resources for those experiencing food insecurity. Guest: Heejin Lee, PhD, postdoctoral research fellow, department of nutrition, Harvard T.H. Chan School of Public Health Show Notes Read Dr. Lee's article, “Food Insecurity and Risk of Dementia and Cognitive Impairment With No Dementia in US Older Adults,” published by JAMA Network Open online. Learn more about Dr. Lee at her profile on the Harvard T.H. Chan School of Public Health website. Read the Household Food Security report, "Household Food Security in the United States in 2024," on the U.S. Department of Agriculture's Economic Research Service website. Listen to our episode with Dr. Beth Olson, “How Ultra‑Processed Foods Impact Your Overall Health,” mentioned at 11:00, on our website, Spotify, Apple Podcasts or wherever you listen. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production. Learn about and pre-order Dr. Chin's book, When Memory Fades: What to Expect at Every Stage, from Early Signs to Full Support for Alzheimer's and Dementia, out June 2, 2026.

Why does bipolar disorder take years - sometimes decades - to diagnose accurately? And what if artificial intelligence could change that?AI researcher and mood disorder psychiatrist Dr. John-Jose Nunez breaks down the hidden challenges behind bipolar diagnosis and explains how AI could reshape the way we diagnose bipolar disorder. By uncovering new patterns, AI may help doctors see what's been overlooked - earlier and more accurately than ever before. But how close are we to that reality, and what are the limits?(00:00) AI Is Changing How Doctors Diagnose Bipolar (03:16) How Accurate Is AI? Doctors vs AI(06:50) Human-in-the-loop(09:15) Will AI Replace Psychiatrists?Bipolar Explained is a new #talkBD series spotlighting expert perspectives on the history, biology, and management of bipolar disorder.---Dr. John-Jose Nunez is a psychiatrist and clinical researcher whose work bridges psychiatry and computer science, with a focus on using computational approaches including artificial intelligence, machine learning and natural language processing to improve mental health outcomes. He holds an MD and MSc in Computer Science from UBC, and is a Fellow of the Royal College of Physicians of Canada (Psychiatry). Dr. Nunez is an Assistant Professor at the University of British Columbia, a member of the CREST.BD network, and serves as the Associate Medical Director of Supportive Care at BC Cancer.His research aims to use computational methods like artificial intelligence to help patients with mood disorders such as bipolar disorder and depression, and patients experiencing both cancer and mental illness. His thesis work has led to two high-profile publications in JAMA Network Open and Communications Medicine, which garnered international media coverage. His work has been supported by the UBC Institute of Mental Health and the BC Cancer Foundation. More on Dr. Nunez: https://nunezlab.ca

In 2025, U.S. digital health startups raised $14.2 billion. AI-enabled companies captured 54% of it. Every prediction in every roundup carries one quiet assumption underneath it. The patient on the receiving end can use what's being built. The Pew data from January says something different. Two trajectories. One looks like progress in aggregate. The other looks like the patients with the worst health outcomes being structurally locked out of the system that's being built. Chris Boyer and Reed Smith examine what happens when digital strategy and health equity stop being parallel tracks and become the same problem. Why the 2026 AI investment narrative quietly assumes a digitally capable patient, and what the population data actually shows The smartphone-dependent patient most health systems haven't internalized, and why portal UX fails them by design Why disparities in patient portal access are widening for low-income, less-educated and 65-plus populations, even as overall use rises What the 2025 cancellation of federal digital equity funding means for health systems whose patient panels actually need the work done Modality mix as the reframe: digital, phone, in-person and printed channels as a portfolio allocated by segment, not a hierarchy everyone migrates toward The University of Michigan study published in JAMA Network Open in October is the one to anchor on. Researchers looked at 511 hospitals in 51 counties in 17 states where census data showed at least 300,000 LEP residents. 29% of those hospitals offered the patient portal login in English only. 60% offered English plus Spanish. 11% offered three or more languages. In counties specifically chosen because they have hundreds of thousands of patients who don't speak English at home. If your most-invested-in digital experience reaches the patients who already had the most options, and barely touches the patients with the worst outcomes, what is your digital strategy actually optimizing for? Mentions from the Show: Pew Research Center, NPORS 2025, January 2026: https://www.pewresearch.org/short-reads/2026/01/08/internet-use-smartphone-ownership-digital-divides-in-u-s/ Pew Research Center, Internet/Broadband Fact Sheet, December 2025: https://www.pewresearch.org/internet/fact-sheet/internet-broadband/ Pew Research Center, Mobile Fact Sheet, December 2025: https://www.pewresearch.org/internet/fact-sheet/mobile/ OATS / Benton Institute, 19 Million Older Adults Lack Broadband, 2025: https://www.benton.org/blog/19-million-older-adults-lack-broadband Shah & Fiala, Disparities in Patient Portal Access and Utilization, Journal of General Internal Medicine, January 2025: https://link.springer.com/article/10.1007/s11606-025-09359-z Chen et al. (U-Michigan), Language Barriers and Access to Hospital Patient Portals in the US, JAMA Network Open, October 2025: https://ihpi.umich.edu/news-events/news/language-barriers-health-care-have-fallen-not-online-study-shows Healthcare Dive, Top healthcare AI trends in 2026 (Rock Health funding data), January 2026: https://www.healthcaredive.com/news/top-healthcare-ai-artificial-intelligence-trends-2026/809493/ HIT Consultant / CB Insights, Q1 2026 Digital Health Funding, April 2026: https://hitconsultant.net/2026/04/20/digital-health-funding-q1-2026-ai-ma-rebound/ Chief Healthcare Executive, AI in health care: 26 leaders offer predictions for 2026, January 2026: https://www.chiefhealthcareexecutive.com/view/ai-in-health-care-26-leaders-offer-predictions-for-2026 JMIR, Bridging Rural America's Digital Divide in Health Care, December 2025: https://www.jmir.org/2025/1/e88833 Johns Hopkins Bloomberg School, Bridging the Digital Divide in Health Care: A New Framework for Equity, January 2025: https://publichealth.jhu.edu/2025/bridging-the-digital-divide-in-health-care-a-new-framework-for-equity NPR, How ending the Digital Equity Act has disrupted programs to help people get online, November 2025: https://www.npr.org/2025/11/12/nx-s1-5594805/how-ending-the-digital-equity-act-has-disrupted-programs-to-help-people-get-online ScienceDirect narrative review, Addressing language barriers in U.S. healthcare, November 2025: https://www.sciencedirect.com/science/article/pii/S2772632025000418 Reed Smith on LinkedIn: https://www.linkedin.com/in/reedtsmith/ Chris Boyer on LinkedIn: https://www.linkedin.com/in/chrisboyer/ Chris Boyer website: http://www.christopherboyer.com/ Chris Boyer on BlueSky: https://bsky.app/profile/chrisboyer.bsky.social Reed Smith on BlueSky: https://bsky.app/profile/reedsmith.bsky.social Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode explores what massage and acupuncture can genuinely help with, where the benefits appear to be mostly short term, and where the evidence simply does not support the bigger claims.Massage and acupuncture are widely used, and many people spend real time, money, and hope on them. I walk through an important distinction: feeling better is not the same as changing the underlying problem or speeding healing. A treatment may reduce pain, soreness, anxiety, or tension without actually fixing injured tissue or altering the course of recovery.I also explain why the research can be so tricky to interpret. When massage or acupuncture is compared with no treatment, the results often look encouraging. But when they are compared with a sham treatment, the benefits usually shrink. That matters because even light touch, attention, expectation, and the ritual of care may create real symptom relief on their own. I discuss this challenge using a recent JAMA Network Open review.For massage, the strongest case is short-term symptom relief. I review studies showing benefit after surgery, including improved pain, anxiety, and relaxation in cardiac surgery patients and better perceived comfort after colorectal surgeryBut when massage is studied for neck pain, low back pain, or post-exercise recovery, the picture is much more mixed. It may help soreness or pain in the short term, but it does not clearly improve function, healing, or athletic performance, as seen in reviews on neck pain, low back pain and sports recoveryFor acupuncture, I look at the areas where evidence is more promising and where it is less convincing. A recent review found possible benefit for delayed vomiting during cancer care and a Cochrane review found that acupuncture may help with migraine preventionFor chronic low back pain, acupuncture may help compared with no treatment, but it is not clearly better than sham acupuncture, according to a Cochrane review.  For tennis elbow, the evidence suggests possible short-term pain relief, but not strong proof of lasting benefit or faster recovery, based on this systematic reviewTakeaways: Massage seems most helpful for relaxation, short-term relief, and reducing soreness, but not for clearly accelerating healing. Acupuncture appears to have narrower evidence-based uses, especially migraine prevention and possibly delayed vomiting in cancer care. When claims expand into fixing injuries, correcting structure, boosting immunity, or treating a wide range of unrelated conditions, the evidence becomes much weaker.Send us Fan Mail

Send us Fan MailThe transfusion threshold consensus is here — but practice hasn't fully caught up. In the second episode of On with VON, Ben and Daphna sit down with Dr. Roger Soll and Dr. Ravi Patel to extend the conversation from the Vermont Oxford Network Grand Rounds on evidence to practice for transfusion thresholds.The core finding across trials is consistent: lower thresholds for both packed red blood cells and platelets appear safe. The guidelines are freely available in JAMA Network Open and actionable — 11, 10, 9 grams per deciliter across the first three weeks for infants on respiratory support. So why hasn't practice shifted uniformly?The group works through the populations the trials didn't fully capture — hypoxic-ischemic encephalopathy, the most premature infants, and babies in the first week of life when intraventricular hemorrhage risk peaks. On NEC and feeding during transfusion: the data may surprise you. On transfusion volume and infusion duration: an underappreciated variable, particularly for platelets.The episode closes with practical guidance on implementing transfusion guidelines at the unit level — who needs to be in the room, how informatics tools can support decision-making, and why understanding protocol deviations matters as much as the guidelines themselves.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailIn this Journal Club episode, Ben reviews a secondary analysis of the CALI trial, published in JAMA Network Open, examining two-year neurodevelopmental and pulmonary outcomes in preterm infants who received early caffeine combined with LISA versus caffeine and CPAP alone. Building on the original CALI trial's finding that early caffeine prior to LISA reduced intubation rates and BPD, this follow-up asks the next logical question: does that early advantage translate into better long-term outcomes? Ben walks through the Bayley scores, gross motor function, ASQ-3, M-CHAT, and pulmonary outcomes — and delivers a reassuring if not statistically significant picture. Tune in for a deep dive into the evidence behind one of neonatology's most debated respiratory strategies!----Two-Year Outcomes of Less Invasive Surfactant Administration Among Preterm Neonates: A Secondary Analysis of a Randomized Clinical Trial. Dorner RA, Morales A, Banerji A, Uy C, Ines F, Finer N, Vaucher Y, Katheria AC.JAMA Netw Open. 2026 Mar 2;9(3):e263852. doi: 10.1001/jamanetworkopen.2026.3852.PMID: 41915392Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

What if your thoughts were creating physical changes in your body? In this episode, we are looking at the science behind mindset and how your brain, your expectations, and your thought patterns influence your health in very real ways. From negativity bias to the nocebo and placebo effects, I break down the research that shows how your mind impacts stress, symptoms, and healing. You will learn why fear-based thinking feels automatic, how it affects your body, and how to start shifting your thoughts in a way that actually works. This is not about positive thinking. It is about understanding how your brain works and learning how to guide it.   Resources Mentioned: Work with Laura: https://www.thebreastcancerrecoverycoach.com/health  Download the app: https://apps.apple.com/us/app/breast-cancer-recovery-coach/id6720763813       REFERENCES Baumeister, R.F., Bratslavsky, E., Finkenauer, C., & Vohs, K.D. (2001). Bad is stronger than good. Review of General Psychology, 5(4), 323-370. https://journals.sagepub.com/doi/abs/10.1037/1089-2680.5.4.323  Rozin, P., & Royzman, E.B. (2001). Negativity bias, negativity dominance, and contagion. Personality and Social Psychology Review, 5(4), 296-320. https://journals.sagepub.com/doi/10.1207/S15327957PSPR0504_2  Beecher, H.K. (1955). The powerful placebo. Journal of the American Medical Association, 159(17), 1602-1606. https://jamanetwork.com/journals/jama/fullarticle/303530  de la Fuente-Fernández, R., Ruth, T.J., Sossi, V., Schulzer, M., Calne, D.B., & Stoessl, A.J. (2001). Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease. Science, 293(5532), 1164-1166. https://www.science.org/doi/10.1126/science.1060937  Kaptchuk, T.J., Friedlander, E., Kelley, J.M., et al. (2010). Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLOS ONE, 5(12), e15591. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0015591  Benedetti, F., Amanzio, M., Vighetti, S., & Asteggiano, G. (2006). The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. Journal of Neuroscience, 26(46), 12014-12022. https://www.jneurosci.org/content/26/46/12014 Haas, J.W., Bender, F.L., Ballou, S., Kelley, J.M., Wilhelm, M., Miller, F.G., Rief, W., & Kaptchuk, T.J. (2022). Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: A systematic review and meta-analysis. JAMA Network Open, 5(1), e2143955. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788172     Let's Connect! If this episode helped you breathe a little easier, please share it with a friend or leave a review. Every share helps spread this message of hope, healing, and whole-person wellness.

JEMS Development Editor Mike Brown sits down with Dr. Stacy Shackelford, a coauthor of a new JAMA Network Open paper, to unpack findings about calcium abnormalities in trauma patients. The authors tracked a cohort of 1,270 trauma patients arriving at three level I trauma centers and found that 22% presented with hypocalcemia and 5% with hypercalcemia. Early mortality varied significantly by calcium status: 11.9% among hypocalcemic patients, 4.3% among eucalcemic patients, and 22.8% among hypercalcemic patients. Although hypercalcemia was less common than hypocalcemia, it was associated with substantially worse early mortality, suggesting the need for further research into the underlying mechanisms.

Send us Fan MailThis week on The Incubator Podcast, Ben and Daphna cover five topics spanning clinical practice, emerging technology, and neonatal policy. They open with a large Swedish national cohort study from JAMA Network Open examining early prophylactic hydrocortisone in extremely preterm infants, debating whether a blanket approach to BPD prevention holds up across gestational ages and in the presence of chorioamnionitis.They then take a critical look at predischarge car seat tolerance screening, questioning whether this decades-old AAP recommendation still earns its place in routine NICU discharge planning given its failure to reduce mortality or readmissions.The conversation shifts to BPD-associated pulmonary hypertension, reviewing a PPHNet study that challenges whether current grading criteria and assessment timepoints adequately capture pulmonary vascular disease severity. They then explore oculomics — a compelling new frontier in which deep learning applied to routine ROP screening images can predict BPD and pulmonary hypertension weeks ahead of clinical diagnosis.The week closes with a Neo News policy discussion on the regulatory pressures threatening freestanding birth centers nationwide, and the downstream consequences for maternal health equity, newborn screening, and neonatal advocacy.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ 2026. Discussion by:Guest:Susan Kucher, MDProgram Director - Abington Family Medicine Residency Program Jefferson Health2. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial. JAMA. Discussion by:Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington3. Prevalence of Youth Overweight, Obesity, and Severe Obesity. JAMA Network Open. Discussion by:  Guest:Neil Skolnik, MDProfessor of Family and Community MedicineSidney  Kimmel  Medical College Thomas Jefferson UniversityAssociate Director - Family Medicine Residency ProgramJefferson Health – Abington4. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine 2026. Discussion by:Guest:Griffin Johnson, MDResident - Abington Family Medicine Residency Program Jefferson HealthMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Send us Fan MailIn this Journal Club episode, Ben and Daphna review a systematic review and meta-analysis from JAMA Network Open questioning the clinical value of predischarge car seat tolerance screening (CSTS). Driven by data suggesting that testing does not reduce 30-day mortality or hospital readmissions, they discuss the high failure rates, varying definitions of bradycardia and desaturation, and the unintended consequence of prolonged NICU stays. They also highlight the practical reality of CSTS in ensuring parents actually have an appropriate car seat at discharge. Tune in for a critical look at whether this 1991 AAP recommendation still holds up today!----Predischarge Car Seat Tolerance Screening in Preterm and At-Risk Full-Term Infants: A Systematic Review and Meta-Analysis. King BC, Dalvie N, Hay S, Jensen EA, Zupancic JAF.JAMA Netw Open. 2026 Feb 2;9(2):e2558197. doi:0.1001/jamanetworkopen.2025.58197.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailIn this Daily Journal Club episode, Ben and Daphna review a massive Swedish national cohort study from JAMA Network Open examining early prophylactic hydrocortisone in extremely preterm infants. They discuss the targeted regimens used, differences in gestational age outcomes, and whether a blanket prophylactic approach is truly effective for preventing BPD. With impressive data covering 98% of all NICU admissions in Sweden, the hosts debate the nuances of targeting 24 to 25-weekers versus older preemies and the potential confounding impact of chorioamnionitis. Tune in for your daily snack of evidence-based medicine and insights into optimizing NICU steroid protocols!----Early Prophylactic Hydrocortisone and Bronchopulmonary Dysplasia-Free Survival in Extremely Preterm Infants. Smedbäck V, Björklund LJ, Flisberg A, Wróblewska J, Baud O, Wejryd E, Ådén U.JAMA Netw Open. 2026 Feb 2;9(2):e2560146. doi:10.1001/jamanetworkopen.2025.60146.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Emotion Regulation Individual Therapy for Adolescents (ERITA) and its internet-delivered version (IERITA) is just one of a couple of treatments developed specifically to address nonsuicidal self-injury (NSSI) among adolescents. In this episode, Dr. Johan Bjureberg from the Karolinska Institute in Stockholm, Sweden walks us through in detail each of the 11 sessions of IERITA and IERITA's 6 parallel sessions for parents. Learn more about Dr. Bjureberg's work here, and follow his research lab and their projects and publications at Emotion regulation, Self-injury, Suicide, and Intervention (ESSI) here. Below are links to his research on ERITA/IERITA referenced in this episode: Bjureberg, J., Ojala, O., Hesser, H., Häbel, H., Sahlin, H., Gratz, K. L., Tull, M. T., Knutsson, E. C., Hedman-Lagerlöf, E., Ljótsson, B., & Hellner, C. (2023). Effect of internet-delivered Emotion Regulation Individual Therapy for Adolescents with Nonsuicidal Self-Injury Disorder: A randomized clinical trial. JAMA Network Open, 6(7), e2322069. Bjureberg, J., Sahlin, H., Hedman-Lagerlof, E., Gratz, K. L., Tull, M. T., Jokinen, J., Hellner, C., & Ljotsson, B. (2018). Extending research on emotion regulation individual therapy for adolescents (ERITA) with nonsuicidal self-injury disorder: Open pilot trial and mediation analysis of a novel online version. BMC Psychiatry, 18, 326. Bjureberg, J., Sahlin, H., Hellner, C., Hedman-Lagerlof, E., Gratz, K. L., Bjarehed, J., Jokinen, J., Tull, M. T., & Ljotsson, B. (2017). Emotion regulation individual therapy for adolescents with nonsuicidal self-injury disorder: A feasibility study. BMC Psychiatry, 17, 411. Follow Dr. Westers on Instagram and Twitter (@DocWesters). To join ISSS, visit itriples.org and follow ISSS on Facebook and Twitter (@ITripleS). The Psychology of Self-Injury podcast has been rated #5 by Feedspot in their "Best 20 Clinical Psychology Podcasts" and by Welp Magazine in their "20 Best Injury Podcasts."

Protecting nurses and healthcare workers physically and mentally is not just one component of the Safer Together National Action Plan; it may be the one that holds all the others together.   In this third episode of our Safer Together series, Patricia McGaffigan, RN, MS, Vice President of Safety at IHI, President of the Certification Board for Professionals in Patient Safety, and co-chair of the National Steering Committee for Patient Safety talks with Christine Pabico, Senior Director of the American Nurses Credentialing Center's Pathway to Excellence and Well-Being Excellence Programs.  Patricia and Christine trace the development of ANCC's Well-Being Excellence Credential, the first of its kind to encompass the entire workforce across every type of care setting. We also hear from two of its pilot organizations, Children's National Hospital in Washington, D.C., and BayCare Health System in Tampa Bay, to hear how they became certified through the ANCC Wellbeing Certification and what that means for their organizations.   Patricia McGaffigan, MS, RN, CPPS  ·  Senior Advisor for Safety, Institute for Healthcare Improvement (IHI); President, Certification Board for Professionals in Patient Safety; Co-chair, National Steering Committee for Patient Safety  Christine Pabico, PhD, RN, NE-BC, FAAN  ·  Senior Director, Pathway to Excellence and Well-Being Excellence, American Nurses Credentialing Center (ANCC)  Nikki Daily  ·  Chief Team Resources Officer, BayCare Health System   Rocky Hauch, DNP, RN, PCCN  ·  Advanced Professional Development Practitioner and Nurse Well-Being Lead, BayCare Health System  Trish Shucoski, DNP, MSN, RN, NEA-BC  ·  Chief Nurse Executive, BayCare Health System  Simmy King, DNP, MS, MBA, NI-BC, NE-BC, CHSE, FAAN  ·  Chief Nursing Informatics and Education Officer; Associate Professor of Pediatrics, The George Washington University School of Medicine    Safer Together Series In the first episode of our Safer Together Series, Donald Berwick, MD, co-founder and President Emeritus of the Institute for Healthcare Improvement, and Patricia McGaffigan, RN, MS, Vice President of Safety at IHI, President of the Certification Board for Professionals in Patient Safety, and co-chair of the National Steering Committee for Patient Safety, issued a call to action: safety is not a matter of individual effort; it is a total system responsibility, built on four interlocking pillars, one of which is workforce safety and well-being.   In the second episode, Kelly Randall, PhD, Vice President for Patient Safety and Regulatory Services at Ascension, where she leads the health system's comprehensive patient safety program, high reliability strategy, and system-wide deployment of the Safer Together National Action Plan, showed us what it looks like to answer that call, shifting culture across nearly 100 hospitals, one huddle, one conversation, one near-miss at a time.    Resources   1. The Foundational Workforce-Safety Lucian Leape Institute. (2013). Through the Eyes of the Workforce: Creating Joy, Meaning, and Safer Health Care. Boston: National Patient Safety Foundation. https://www.ihi.org/library/publications/through-eyes-workforce-creating-joy-meaning-and-safer-health-care  Gandhi, T. K., Kaplan, G. S., Leape, L., et al. (2018). Transforming concepts in patient safety: A progress report. BMJ Quality & Safety, 27(12), 1019–1026. https://doi.org/10.1136/bmjqs-2018-008768 https://pmc.ncbi.nlm.nih.gov/articles/PMC6288701/    2. The Safer Together National Action Plan  National Steering Committee for Patient Safety. (2020). Safer Together: A National Action Plan to Advance Patient Safety. Boston, MA: Institute for Healthcare Improvement. https://www.ihi.org/partner/initiatives/national-steering-committee-patient-safety/national-action-plan-advance-patient-safety  Integrating the Safer Together National Action Plan to Improve Nurse-Led Models Focused on Patient Safety. PubMed. https://pubmed.ncbi.nlm.nih.gov/40876046/    3. Nurse Burnout and Patient Safety  Li, L. Z., Yang, P., Singer, S. J., Pfeffer, J., Mathur, M. B., & Shanafelt, T. (2024). Nurse burnout and patient safety, satisfaction, and quality of care: A systematic review and meta-analysis. JAMA Network Open, 7(11), e2443059. https://doi.org/10.1001/jamanetworkopen.2024.43059  Getie, A., Ayenew, T., Amlak, B. T., Gedfew, M., Edmealem, A., & Kebede, W. M. (2025). Global prevalence and contributing factors of nurse burnout: An umbrella review of systematic reviews and meta-analyses. BMC Nursing, 24(1), 596. https://doi.org/10.1186/s12912-025-03266-8  Smiley, R. A., Kaminski-Ozturk, N., Reid, M., et al. (2025). The 2024 National Nursing Workforce Survey. Journal of Nursing Regulation, 16(1), S1–S88. https://doi.org/10.1016/S2155-8256(25)00047-X    4. Workplace Violence Against Nurses  Pascale, A., George, N., Potter, C., & Warshawsky, N. E. (2025). Alarming rise in nurse assaults: Urgent call for legislation. Nurse Leader, 23(3), 321–327. https://doi.org/10.1016/j.mnl.2024.12.012  Wolf, L. A., Delao, A. M., & Perhats, C. (2014). Nothing changes, nobody cares: Understanding the experience of emergency nurses physically or verbally assaulted while providing care. Journal of Emergency Nursing, 40(4), 305–310. https://doi.org/10.1016/j.jen.2013.11.006    5. ANCC Well-Being Excellence Credential  Carson, W., & Bates, M. (2024). Elevating professional well-being in healthcare: A crosswalk of the NIOSH Impact Wellbeing campaign and the ANCC Pathway to Excellence Framework. Nursing Administration Quarterly. https://pmc.ncbi.nlm.nih.gov/articles/PMC11373476/  American Nurses Credentialing Center. (2025). ANCC Well-Being Excellence Credential. NursingWorld.org. https://www.nursingworld.org/organizational-programs/well-being-excellence    6. Nurse Well-Being: Building Peer and Leadership Support Program  American Nurses Foundation. (n.d.). Nurse well-being: Building peer and leadership support program. NursingWorld.org. https://www.nursingworld.org/foundation/programs/nurse-wellbeing/    7. Healthy Nurse, Healthy Nation  American Nurses Association. (n.d.). Healthy Nurse, Healthy Nation. https://www.healthynursehealthynation.org/     

Send a textIn this Journal Club episode, Ben and Daphna review the eye-opening results of the NeoDry Trial recently published in JAMA Network Open. They explore the clinical rationale of whether drying very preterm infants before applying a plastic wrap in the delivery room improves rates of normothermia upon NICU admission. While the intervention did not significantly improve temperatures, it unexpectedly revealed an alarming increased mortality risk for the smallest neonates. Tune in as they break down the study's design, discuss the potential causes for this stark safety signal, and highlight the ongoing challenge of maintaining thermoregulation for our most vulnerable preemies!----Drying Very Preterm Infants Before Plastic Wrapping at Birth: A Randomized Clinical Trial. Cavallin F, Doglioni N, Risso FM, Monari CB, Aversa S, Troiani S, Battajon N, Moschella S, Villani PE, Vedovato S, Maiorca D, Frezza S, Lista G, Laforgia N, Mondello I, Sibona I, Staffler A, Pratesi S, Paviotti G, De Bernardo G, Lama S, Miselli F, Bua J, Gitto E, Pesce S, Baraldi E, Trevisanuto D; NEODRY Trial Group.JAMA Netw Open. 2026 Mar 2;9(3):e2556902. doi: 10.1001/jamanetworkopen.2025.56902.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Feeling dismissed by your doctor? In this episode, Nurse Doza invites you to stop Googling your symptoms and start getting real answers in a live ask me anything format. Every Wednesday at 1 PM Central, the School of Doza hosts a one-hour group consult where you can ask a functional practitioner anything — from hormones and gut health to autoimmune disorders and thyroid issues. Nothing is off limits. Try it free for one week.

Send a textCan you predict when “bad things” will happen to your health—and more importantly, can you do anything about it? In this episode, I break down which prediction tools actually help you live long and well (because you can act on them), and which ones are mostly expensive fortune-telling. Joined by cardiologist Dr. Anthony Pearson (author of The Skeptical Cardiologist), we dig into heart-risk calculators, dementia genetics, and why biological age clocks aren't ready for prime time.Guest: Dr. Anthony Pearson, cardiologist and writer of The Skeptical Cardiologist (Substack)Key topics & takeawaysWhy “prediction” only matters if it changes what you do—and improves real outcomes.A red flag to watch for: is the person promoting the tool also selling the test, supplements, or “hacks” to fix it?A sobering reality check: even doctors' YouTube claims often lack strong evidence (and the least evidence-based content gets more views).Heart disease risk equations: the gold standard in prediction because we can reduce risk factors (BP, LDL/ApoB, smoking, diabetes) and clinical trials show outcomes improve.But even good tools miss people: a study of

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-472 Overview: The transition from hospital to home is a valuable period for patients and clinicians. In this episode, we discuss which patients require follow-up, what should be reviewed during these appointments, and when follow-up should take place to help improve patient outcomes. Episode resource links: Anderson, T. S., Herzig, S. J., Marcantonio, E. R., Yeh, R. W., Souza, J., & Landon, B. E. (2024, April). Medicare transitional care management program and changes in timely postdischarge follow-up. In JAMA Health Forum (Vol. 5, No. 4, pp. e240417-e240417). American Medical Association. Anderson, T. S., Wilson, L. M., Wang, B. X., Steinman, M. A., Schonberg, M. A., Marcantonio, E. R., & Herzig, S. J. (2025). Medication Errors and Gaps in Medication Discharge Planning for Hospitalized Older Adults: A Prospective Cohort Study. Journal of general internal medicine, 1-10.   Balasubramanian, I., Andres, E. B., & Malhotra, C. (2025). Outpatient follow-up and 30-day readmissions: a systematic review and meta-analysis. JAMA Network Open, 8(11), e2541272-e2541272. Guest: Mariyan L. Montaque, DNP, FNP-BC Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-472 Overview: The transition from hospital to home is a valuable period for patients and clinicians. In this episode, we discuss which patients require follow-up, what should be reviewed during these appointments, and when follow-up should take place to help improve patient outcomes. Episode resource links: Anderson, T. S., Herzig, S. J., Marcantonio, E. R., Yeh, R. W., Souza, J., & Landon, B. E. (2024, April). Medicare transitional care management program and changes in timely postdischarge follow-up. In JAMA Health Forum (Vol. 5, No. 4, pp. e240417-e240417). American Medical Association. Anderson, T. S., Wilson, L. M., Wang, B. X., Steinman, M. A., Schonberg, M. A., Marcantonio, E. R., & Herzig, S. J. (2025). Medication Errors and Gaps in Medication Discharge Planning for Hospitalized Older Adults: A Prospective Cohort Study. Journal of general internal medicine, 1-10.   Balasubramanian, I., Andres, E. B., & Malhotra, C. (2025). Outpatient follow-up and 30-day readmissions: a systematic review and meta-analysis. JAMA Network Open, 8(11), e2541272-e2541272. Guest: Mariyan L. Montaque, DNP, FNP-BC Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Angenommen, Dein Personalausweis sagt, Du bist 46. Dann erzählt Dein Körper vielleicht die Geschichte einer 55-Jährigen – oder die eines 37-Jährigen. Der Unterschied? Dein biologisches Alter. Und das kannst Du beeinflussen.Am Ende dieser Folge weißt Du, was biologisches Alter wirklich bedeutet, wie Du es messen kannst – von DNA-Tests bis Wearables – und welche drei Hebel auf Basis aktueller Forschung am effektivsten sind. Mark teilt seine eigenen WHOOP-Daten aus 2025: vom Bestwert im Sommer über Bundeswehrübung und USA-Jetlag bis zum Buchlaunch-Stress. Das Ergebnis? Trotz allem netto jünger geworden.Du lernst, warum VO₂max der stärkste Prädiktor für Deine Lebenserwartung ist, warum Schlafkonsistenz wichtiger ist als Schlafdauer – und warum 90 Minuten Krafttraining pro Woche Dich um fast 4 Jahre verjüngen können.____________*WERBUNG: Infos zum Werbepartner dieser Folge und allen weiteren Werbepartnern findest Du hier.Nur diese Woche: Sichere Dir Dein #DRNBLBR Gym Towell – solange vorrätig: drnblbr.de.____________Erwähnte Tools und Ressourcen:Fitnesstracker:WHOOP (Fitness-Tracker mit umfassendem Healthspan-Feature) – 1 Monat gratis über diesen Link.Cerascreen Genetic Age Test (epigenetischer Test, Horvath-Uhr)Polar Loop (kein Abo, weniger Funktionen)Amazfit Helio Strap (kein Abo, Basisfunktionen)Waage:Withings Body ScanBücher:„Looking Good Naked – Die Gesamtausgabe“ von Mark Maslow (2025)Podcast und Artikel:Folge 466: Die neue Wissenschaft vom Schlaf – mit Dr. Peter SporkArtikel: Genetic Age Test: Die Wahrheit über Dein biologisches Alter?Testbericht:c't Fitnessarmband-Vergleichstest (Helio Strap, Polar Loop, WHOOP)Forschungseinrichtung:Buck Institute for Research on Aging (Whoop-Forschungspartner)Literatur:Horvath, S. (2013). DNA methylation age of human tissues and cell types. Genome Biology, 14(10), R115.Fitzgerald, K.N. et al. (2021). Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging, 13(7), 9419–9432.Mandsager, K. et al. (2018). Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Network Open, 1(6), e183605.Windred, D.P. et al. (2024). Sleep regularity is a stronger predictor of mortality risk than sleep duration. SLEEP, 47(1), zsad253.Leong, D.P. et al. (2015). Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. The Lancet, 386(9990), 266–273.Tucker, L.A. (2024). Telomere Length and Biological Aging: The Role of Strength Training in 4814 US Men and Women. Biology, 13(11), 883.c't Magazin (2025). Fitnessarmbänder ohne Display im Test: Helio Strap, Polar Loop, WHOOP MG. Ausgabe 25, S.102.Produktlinks sind Affiliate-Links.____________Shownotes und Übersicht aller Folgen.Trag Dich in Marks Dranbleiber Newsletter ein.Entdecke Marks Bücher.Folge Mark auf Instagram, Facebook, Strava, LinkedIn. Hosted on Acast. See acast.com/privacy for more information.

In this special series on Automated Insulin Delivery our host, Dr. Neil Skolnik will discuss with the benefits of Automated Insulin Delivery for people with Type 2 Diabetes with two master clinicians, one an diabetes specialist, the other a primary care doctor. This special episode is supported by an independent educational grant from Insulet. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Davida Kruger, MSN, APN-BC,BC-ADM,  Henry Ford Health, Detroit, Michigan. Past Chair of the American Diabetes Associations Research Foundation, Past president, Health Care and Education of the American Diabetes Association. Susan Kuchera, M.D. - Program Director of the Jefferson Health Abington Family Medicine Residency Program, Clinical Associate Professor of Family and Community Medicine in the Sidney Kimmel Medical College of Thomas Jefferson University Selected references: Automated Insulin Delivery in Adults With Type 2 Diabetes A Nonrandomized Clinical Trial. JAMA Network Open. 2025;8(2):e2459348. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.  N Engl J Med 2025;392:1801-12 Automated Insulin Pump in Type 2 Diabetes – Editorial - N Engl J Med 2025;392:1862-1863

A JAMA Network Open consensus guide standardizes adult UTI triage for telehealth and in-person care. Nonpregnant women with classic cystitis symptoms and no resistance risks may receive empiric antibiotics without testing; men and higher-risk women require urinalysis with culture before treatment. Urine color or odor alone does not justify testing, and urgent evaluation is advised for suspected complicated infection or sepsis. A Danish registry study in JAMA Internal Medicine found SGLT2 inhibitors offer greater kidney protection than GLP-1 receptor agonists in type 2 diabetes. Long-term ASPREE follow-up in JAMA Oncology showed low-dose aspirin did not lower cancer incidence and increased cancer-related mortality in older adults.

Joining this month's episode of The Scope of Things is Joseph Kim, chief strategy officer of ProofPilot, who talks about his company's first-ever CORE Symposium, where pharma pros shared practical solutions to age-old trial challenges. Kim provides a pragmatic viewpoint on the problematic trio of clinical trials—study execution, recruitment, and engagement—and what change agents are needed to pave the way forward and find an exit from the bottlenecks. Plus, host Deborah Borfitz delivers the latest on a planned mapping of clinical trial deserts, the high cost of accelerated FDA approvals, the best states for cancer research, the world's first in-ear EEG system getting approved, and a new smartphone-based outcome measure for sleep studies.  News Roundup Financial hurdles to trial enrollment Study in the Journal of the National Comprehensive Cancer Network News on the Case Western Reserve University website  Accelerated cancer drug approvals Study in BMJ Medicine Best states for cancer research Blog on SmileHub website In-ear EEG devices Article in Diagnostics World News Ecological momentary assessment in sleep-focused trial Study in JAMA Network Open   Guest Joseph Kim, chief strategy officer for ProofPilot The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

In this special series on Automated Insulin Delivery our host, Dr. Neil Skolnik will discuss with the benefits of Automated Insulin Delivery for people with Type 2 Diabetes. This special episode is supported by an independent educational grant from Insulet. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Davida Kruger, MSN, APN-BC,BC-ADM,  Henry Ford Health, Detroit, Michigan. Past Chair of the American Diabetes Associations Research Foundation, Past president, Health Care and Education of the American Diabetes Association. Ashlyn Smith, MMS, PA-C, DFAAPA, LSC, Distinguished Fellow of the American Academy of PAs, Certified Diabetes Prevention Program Lifestyle Coach, Founder of ELM Endocrinology & Lifestyle Medicine, PLLC., Past President of the American Society of Endocrine Physician Assistants, Adjunct faculty at Midwestern University, Selected references: Automated Insulin Delivery in Adults With Type 2 Diabetes A Nonrandomized Clinical Trial. JAMA Network Open. 2025;8(2):e2459348. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.  N Engl J Med 2025;392:1801-12 Automated Insulin Pump in Type 2 Diabetes – Editorial - N Engl J Med 2025;392:1862-1863

Send us a textIn this Journal Club episode, Ben and Daphna review a salient study from JAMA Network Open examining outcomes of infants born at 21 weeks' gestation at the University of Iowa. They walk through resuscitation practices, early physiologic challenges, survival trends, and short-term developmental outcomes, while placing the data in the broader context of shifting limits of viability. The discussion highlights both cautious optimism and the many unanswered questions that remain as neonatology continues to push the boundaries of what is possible.----Outcomes of Infants Born at 21 Weeks' Gestational Age. Hyland RM, Mat HD, Boly TJ, Thomas BJ, Stanford AH, Harmon HM, Bermick JR, Davila RC, Colaizy TT, Dagle JM, Klein JM, Greiner AL, Bell EF, McNamara PJ; University of Iowa Neonatology Program.JAMA Netw Open. 2025 Dec 1;8(12):e2548211. doi:10.1001/jamanetworkopen.2025.48211.PMID: 41385227 Free PMC article.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

A new JAMA Network Open study found that cutting down social media use to roughly 30 minutes per day had measurable effects on mental health, reducing anxiety by about 16%, depression by about 25%, and insomnia symptoms by 15% Loneliness scores did not change much, which shows that social media can be a lifeline for connection as well as a source of stress Earlier randomized trials from the University of Bath and others also found that a one-week break from platforms like TikTok, Instagram, and Facebook improved wellbeing, depression, and anxiety A short reset is not a cure for depression or anxiety, and does not replace therapy, medication, or crisis care. Still, it can be a realistic experiment that helps you see how specific apps affect your mood, sleep, and focus If you already struggle with your mental health, or if you rely on online communities for support, it makes sense to plan your week carefully and to talk with a trusted health professional about how this kind of experiment fits into your overall care

Scott and Jenny discuss bolusing for Sonic Tater Tots Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Restless leg syndrome (RLS) isn't just a sleep problem — it's a neurological signal that your brain's dopamine and iron systems are under stress, and addressing it early helps protect long-term brain health A JAMA Network Open study found that people with RLS were significantly more likely to develop Parkinson's disease than those without it RLS patients who received treatment had four times fewer Parkinson's diagnoses than untreated individuals, suggesting that managing RLS symptoms supports neurological resilience Iron levels, poor sleep quality, and disrupted waste clearance in the brain all appear to link RLS and Parkinson's, underscoring the importance of restoring iron balance and improving sleep hygiene By optimizing dopamine naturally, maintaining healthy iron levels, getting quality sleep, and staying physically active during the day, you can calm restless legs now and strengthen your brain against degeneration later

California became the first state in the U.S. to ban ultraprocessed foods from public school lunches under the "Real Food, Healthy Kids Act," but the full phase-out won't take effect until 2035 Ultraprocessed foods — packed with vegetable oils, additives, and refined sugars — are engineered to trigger cravings and disrupt metabolism, contributing to childhood obesity, insulin resistance, and fatty liver disease A study in JAMA Network Open found that preschoolers who ate the most ultraprocessed foods had higher body fat, larger waistlines, elevated blood sugar, and lower levels of protective HDL cholesterol The delayed timeline leaves millions of children unprotected for nearly a decade, underscoring the urgent need for parents to remove ultraprocessed foods and vegetable oils from their homes now You can protect your child's long-term health by replacing processed snacks with real foods, eliminating vegetable oils, cooking at home, reducing exposure to junk food ads, and teaching kids how to spot marketing tricks